CamGene Therapeutics is a pre-seed stage gene medicine company focused on revolutionizing hearing loss treatment. Their groundbreaking technology utilizes lipid nanoparticle carriers to deliver mRNA encoding neurotrophic growth factors, aiming for a 50% improvement in outcomes for cochlear implant patients.
In the long term, their goal is to establish a company at the forefront of genetic medicine, advancing platform technologies and treatments for various genetic diseases, particularly hearing loss. In Year 1, CamGene aims to generate feasibility data for improving cochlear implants with LNP-mRNA technology while securing a strong intellectual property position and funding for technology advancement in Year 2.
Status | Active |
Website | https://camgenetx.com/ |
Category | Biotech |
Modality | mRNA |
Headquaters | Cambridge, UK |
Investment Portfolio | Fund Investment |